The 2021 Community HIV Cure Research Workshop will take place virtually this year due to the ongoing COVID-19 pandemic. The workshop sessions will be held on Thursday, March 4 and Friday, March 5, 2021 (right before CROI 2021), and then on Tuesday, March 16, 2021 (after the conference).
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...
On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.
Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.
This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.